Polymorphism of vascular endothelial growth factor gene (VEGF) and matrix metalloproteinase (ММР) genes in primary limb lymphedema

Among the reasons of primary lymphedema development, a certain role belongs to genetic factors. The specific molecular products participate in remodeling of blood and lymphatic vascular networks. Vascular endothelial growth factors (VEGFs) are key regulators of endothelial functions of the cells, which are responsible for lympho- and vasculogenesis. Moreover, matrix metalloproteinases (ММР) may act as regulators of both lymphangiogenesis, and angiogenesis. Since the regulatory regions of VEGFA gene, as well as of ММР genes are polymorphic, one may suggest, that their different expression level, determined by these polymorphisms, could be associated with development of swellings typical for lymphedema.

We have analyzed gene polymorphisms in two regulatory regions of vascular endothelial growth factor-A VEGF-A (rs 699947 and rs 3025039), and matrix metalloproteinase genes MMP2 (rs 2438650), MMP3 (rs 3025058), MMP9 (rs 3918242), and their combinations in the patients with primary lymphedema.

A group of patients with primary lymphedema included 72 subjects (55 women and 17 men) at the age of 18 to 81 years. Control group included 526 inhabitants of Novosibirsk (153 men, 373 women) without chronic diseases, comparable for age with lymphedema patients. We have performed typing of regulatory regions in VEGF (rs 699947, rs 3025039), ММР2 (rs 2438650), ММР3 (rs 3025058), ММР9 genes (rs 3918242). Fifteen complex genotypes have been revealed that were positively associated with disease. Analysis of the gene network topology has outlined the main intergenic interactions upon primary lymphedema development. MMP2 -1306 CC, MMP9 -1562CC and VEGF +936CC arrange the basic knots in the gene network (53% of total interactions). A number of significantly different complex genotypes was revealed at patients with primary lymphedema with normal body mass index (BMI < 25) and obesity (BMI < 30). Hence, frequency of complex genotype VEGF +936 CC: MMP3 -1171 5А6А:MMP9 -1562 CC in the patients with obesity is increased more 5.5-fold compared to the patients with normal BMI.

The data obtained may presume a certain value of the analyzed gene polymorphisms in pathogenesis of primary lymphedema. Topological analysis of gene networks allows to study the structural and functional organization of gene-gene interactions for development of approaches to individyal preventive maintenance and therapy of the disease.

1. Poveshchenko A.F., Nimaev V.V., Lubarsky M.S., Konenkov V.I. Medical and genetical aspects of lymphedema. Meditsinskaya genetika = Medical Genetics, 2010, no. 9, pp. 3-9. (In Russ.)

2. Shevchenko A.V., Prokofyev V.F., Korolev M.A., Omelchenko V.O., Konenkov V.I. Gene polymorphisms of endothelial dysfunction, coactivators of mitochondrial biogenesis and plasminogen/plasmin system in the development of cardiovascular events in rheumatoid arthritis. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice, 2018, Vol. 56, no. 1, pp. 55-59. (In Russ.)

3. Aspelund A., Robciuc M.R., Karaman S., Makinen T., Alitalo K. Lymphatic system in cardiovascular medicine. Circ. Res., 2016, Vol. 118, pp. 515-530.

4. Bennuru S., Nutman T.B. Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog., 2009, Vol. 5, no. 12, e1000688. doi: 10.1371/journal.ppat.1000688.

5. Bennuru S., Maldarelli G., Kumaraswami V., Klion A.D., Nutman T.B. Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections. Am. J. Trop. Med. Hyg., 2010, Vol. 83, no. 4, pp. 884-890.

6. Bruyere F., Melen-Lamalle L., Blacher S., Roland G., Thiry M., Moons L., Frankenne F.., Carmeliet P., Alitalo K., Libert C., Sleeman J.P., Foidart J.M., Noël A. Modeling lymphangiogenesis in a three-dimensional culture system. Nat. Methods., 2008, Vol. 5, no. 5, pp. 431-437.

7. Chou Y.-E., Chen W.-H., Luo C.-B., Yang S.-F. Polymorphism in dural arteriovenous fistula: matrix metalloproteinase-2-1306 C/T as a potential risk factor for sinus thrombosis. J. Throm. Haemost., 2018, Vol. 16, no. 4, pp. 802-808.

8. Couto R.A., Kulungowski A.M., Chawla A.S., Fishman S.J., Greene A.K. Expression of angiogenic and vasculogenic factors in human lymphedematous tissue. Lymphat. Res. Biol., 2011, Vol. 9, no. 3, pp. 143-149.

9. Debrah A.Y., Mand S., Toliat M.R., Marfo-Debrekyei Y., Batsa L., Nürnberg P., Lawson B., Adjei O., Hoerauf A., Pfarr K. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am. J. Trop. Med. Hyg., 2007, Vol. 77, no. 4, pp. 601-608.

10. Debrah L.B., Albers A., Debrah A.Y., Brockschmidt F.F., Becker T., Herold C., Hofmann A., OseiMensah J., Mubarik Y., Fröhlich H., Hoerauf A., Pfarr K. Single nucleotide polymorphisms in the angiogenic and lymphangiogenic pathways are associated with lymphedema caused by Wuchereria bancrofti. Hum. Genomics, 2017, Vol. 11, no. 1, 26. doi: 10.1186/s40246-017-0121-7.

11. Detry B., Erpicum C., Paupert J., Blacher S., Maillard C., Bruyere F., Pendeville H., Remacle T., Lambert V., Balsat C., Ormenese S., Lamaye F., Janssens E., Moons L., Cataldo D., Kridelka F., Carmeliet P., Thiry M., Foidart J-M., Struman I., Noe A. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood, 2012, Vol. 119, no. 21, pp. 5048-5056.

12. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., Wu S., Lang R., Iredale J.P. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest., 2005, Vol. 115, no. 1, pp. 56-65.

13. Froehlich H., Fellmann M., Sueltmann H., Poustka A., Beissbarth T. Large scale statistical inference of signaling pathways from RNAI and microarray data. BMC Bioinformatics., 2007, Vol. 8, no. 1, 386. doi:10.1186/14712105-8-386.

14. Gong J., Zhu S., Zhang Y., Wang J. Interplay of VEGF a and MMP2 regulates invasion of glioblastoma. Tumour Biol., 2014, Vol. 35, no. 12, pp. 11879-11885.

15. Heckman C.A., Holopainen T., Wirzenius M., Keskitalo S., Jeltsch M., Ylä-Herttuala S., Wedge S.R., Jürgensmeier J.M., Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res., 2008, Vol. 68, no. 12, pp. 4754-4762.

16. Jacob-Ferreira A.L.B., Lacchini R., Gerlach R., Passos C.J., Barbosa F.Jr, Tanus-Santos J. A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subject environmentally exposed to mercury. Sci. Total Environ., 2011, Vol. 409, no. 20, pp. 4242-4246.

17. Kelly M.A., Shuaib A., Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol., 2006, Vol. 200, no. 1, pp. 38-49.

18. Mac Gabhann F., Qutub A.A., Annex B.H., Popel A.S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip. Rev. Syst. Biol. Med., 2010, Vol. 2, no. 6, pp. 694-707.

19. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., Lawitts J.A., Benjamin L., Tan X., Manseau E.J., Dvorak A.M., Dvorak H.F. Vascular permeability factor/ vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med., 2002, Vol. 196, no. 11, pp. 1497-1506.

20. Okamoto K., Mimura K., Murawak Y., Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase MMP-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastr. Hepatol., 2005, Vol. 20, no. 7, pp. 1102-1108.

21. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res., 2000, Vol. 37, pp. 443-448.

22. Rigo J.Jr. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia. Mol. Hum. Reprod., 2006, Vol. 12, pp. 233-236.

23. Tammela T., Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell, 2010, Vol. 140, no. 4, pp. 460-476.

24. Whitehurst B., Flister M.J., Bagaitkar J., Volk L., Bivens C.M., Pickett B., Castro-Rivera E., Brekken R.A., Gerard R.D., Ran S. AntiVEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int. J. Cancer, 2007, Vol. 121, no. 10, pp. 2181-2191.

25. Wieczór R., Wieczór A.M., Gadomska G., Stankowska K., Fabisiak J, Suppan K., Pulkowski G., Budzyński J, Rość D. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia. J. Zhejiang Univ. Sci. B, 2016, Vol. 17, no. 11, pp. 842-849.

26. Wynn T.A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis., 2010, Vol. 30. no. 3, pp. 245-257.

27. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab., 2007, Vol. 27, no. 4, pp. 697-709.

28. Zampell J.C., Yan A., Elhadad S., Avraham T., Weitman E., Mehrara B.J. CD4 + cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PloS ONE, 2012, Vol. 7, no. 11, e49940. doi: 10.1371/journal.pone.0049940.